Molecular heterogeneity of localized prostate cancer: more different than alike.
作者信息
Tosoian Jeffrey J, Antonarakis Emmanuel S
机构信息
Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
出版信息
Transl Cancer Res. 2017 Feb;6(Suppl 1):S47-S50. doi: 10.21037/tcr.2017.02.17.
Abstract
摘要
相似文献
1
Molecular heterogeneity of localized prostate cancer: more different than alike.局限性前列腺癌的分子异质性：差异多于相似。
Transl Cancer Res. 2017 Feb;6(Suppl 1):S47-S50. doi: 10.21037/tcr.2017.02.17.
2
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.多灶性局限性前列腺癌的瘤内和瘤间基因组异质性影响分子分类和基因组预后指标。
Eur Urol. 2017 Feb;71(2):183-192. doi: 10.1016/j.eururo.2016.07.008. Epub 2016 Jul 21.
3
Key papers in prostate cancer.前列腺癌的关键论文。
Expert Rev Anticancer Ther. 2014 Nov;14(11):1379-84. doi: 10.1586/14737140.2014.974565. Epub 2014 Oct 28.
4
The Heterogeneity of Prostate Cancer: A Practical Approach.《前列腺癌的异质性：一种实用方法》
Pathobiology. 2018;85(1-2):108-116. doi: 10.1159/000477852. Epub 2018 Jan 31.
5
Prognostic markers in clinically localized prostate cancer.临床局限性前列腺癌的预后标志物
Tech Urol. 1998 Mar;4(1):35-42.
6
Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.基于单细胞测序的局限性前列腺癌中肿瘤内空间基因组异质性。
Eur Urol. 2018 Nov;74(5):551-559. doi: 10.1016/j.eururo.2018.06.005. Epub 2018 Jun 23.
7
Expectant management: an option for localized prostate cancer.期待性管理：局限性前列腺癌的一种选择。
Prostate Cancer Prostatic Dis. 2005;8(4):311-5. doi: 10.1038/sj.pcan.4500824.
9
Impact of genetic targets on prostate cancer therapy.遗传靶点对前列腺癌治疗的影响。
Adv Exp Med Biol. 2013;779:359-83. doi: 10.1007/978-1-4614-6176-0_17.
10
Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores.通过整合阳性核心百分比来剖析局限性前列腺癌风险组的异质性。
Future Oncol. 2018 Jun;14(15):1469-1476. doi: 10.2217/fon-2017-0596. Epub 2018 May 10.
引用本文的文献
1
CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation.CACNA1D 过表达和电压门控钙通道在雄激素剥夺治疗期间的前列腺癌中。
Sci Rep. 2023 Mar 22;13(1):4683. doi: 10.1038/s41598-023-28693-y.
2
Nondestructive protein sampling with electroporation facilitates profiling of spatial differential protein expression in breast tumors in vivo.电穿孔的无损蛋白质采样有助于在体研究乳腺癌组织中空间差异蛋白表达的情况。
Sci Rep. 2022 Sep 23;12(1):15835. doi: 10.1038/s41598-022-19984-x.
3
Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?-a narrative review.前列腺癌的聚焦治疗：从研究性治疗转变为有效的治疗选择真正需要什么？——一篇叙述性综述
Ann Transl Med. 2022 Jul;10(13):755. doi: 10.21037/atm-22-50.
4
Electroporation-based proteome sampling ex vivo enables the detection of brain melanoma protein signatures in a location proximate to visible tumor margins.基于电穿孔的蛋白质组样品采集技术可在接近可见肿瘤边界的位置检测到脑黑色素瘤的蛋白特征。
PLoS One. 2022 May 19;17(5):e0265866. doi: 10.1371/journal.pone.0265866. eCollection 2022.
5
The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype.长链非编码RNA GHSROS将前列腺癌细胞系重编程为更具侵袭性的表型。
PeerJ. 2021 Feb 1;9:e10280. doi: 10.7717/peerj.10280. eCollection 2021.
6
Molecular harvesting with electroporation for tissue profiling.电穿孔法进行分子提取以进行组织剖析。
Sci Rep. 2019 Oct 31;9(1):15750. doi: 10.1038/s41598-019-51634-7.
7
A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.TMEFF2 调控的细胞周期相关基因特征可预测前列腺癌的复发风险。
BMC Cancer. 2019 May 6;19(1):423. doi: 10.1186/s12885-019-5592-6.
8
Molecular correlates of intermediate- and high-risk localized prostate cancer.中高危局限性前列腺癌的分子关联
Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2.
本文引用的文献
1
Prognostic value of prostate biopsy grade: forever a product of sampling.前列腺活检分级的预后价值：永远是抽样的结果。
BJU Int. 2017 Jan;119(1):5-7. doi: 10.1111/bju.13508.
2
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.多灶性局限性前列腺癌的瘤内和瘤间基因组异质性影响分子分类和基因组预后指标。
Eur Urol. 2017 Feb;71(2):183-192. doi: 10.1016/j.eururo.2016.07.008. Epub 2016 Jul 21.
3
The genetic classification of prostate cancer: what's on the horizon?前列腺癌的基因分类：未来发展趋势如何？
Future Oncol. 2016 Mar;12(6):729-33. doi: 10.2217/fon.15.352. Epub 2016 Feb 9.
4
Urinary Biomarkers for Prostate Cancer.前列腺癌的尿液生物标志物
Urol Clin North Am. 2016 Feb;43(1):17-38. doi: 10.1016/j.ucl.2015.08.003.
5
The Molecular Taxonomy of Primary Prostate Cancer.原发性前列腺癌的分子分类学
Cell. 2015 Nov 5;163(4):1011-25. doi: 10.1016/j.cell.2015.10.025.
6
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.拷贝数与转录组学整合为前列腺癌提供风险分层：一项发现与验证队列研究。
EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017. eCollection 2015 Sep.
7
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.基于组织的基因组学在中高危男性自然史队列中增强了前列腺切除术后风险分层。
Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6.
8
Spatial genomic heterogeneity within localized, multifocal prostate cancer.局限性、多灶性前列腺癌的空间基因组异质性。
Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25.
9
Integrative clinical genomics of advanced prostate cancer.晚期前列腺癌的整合临床基因组学
Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001.
10
Genomic Predictors of Outcome in Prostate Cancer.前列腺癌预后的基因组预测因子。
Eur Urol. 2015 Dec;68(6):1033-44. doi: 10.1016/j.eururo.2015.04.008. Epub 2015 Apr 23.
Zotero 插件